Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06213103
Other study ID # CHUBX 2022/36
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 30, 2024
Est. completion date January 2025

Study information

Verified date February 2024
Source University Hospital, Bordeaux
Contact Aurélien TRIMOUILLE, MD
Phone +335 57 82 10 49
Email aurelien.trimouille@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims at characterizing the immune dysfunctions in patients with mitochondrial diseases. This has prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies to alleviate disease burden.


Description:

Mitochondrial pathologies are rare genetic diseases, and affect about 1 in 4300 people. These pathologies are characterized by an energetic deficit that can affect all organs, and can manifest from birth to adulthood. The clinical expression is very heterogeneous, the symptoms can include encephalopathies, myopathies, cardiomyopathies, among others, with frequently "an illegitimate association of symptoms" that add up in a progressive way. These pathologies are related to the presence of pathogenic mutations in the genes of the nuclear genome involved in mitochondrial metabolism, or directly in the genes of the mitochondrial DNA (mtDNA). The immune system dysfunctions associated with mitochondrial diseases remain unknown to date despite the presence of the deleterious variant in leukocytes. Recent studies by group of the investigators and others in animal models clearly show the importance of mitochondrial functions in the regulation of inflammatory and antimicrobial processes. These experimental data are particularly relevant in light of recent clinical studies indicating that patients with mitochondriopathies have a higher rate of bacterial infections compared to control individuals. The investigators hypothesized that immunological parameters assessment in patients will reveal new dysfunctions associated with these pathologies and that some of these parameters will be a prognostic factor in these "step-like" progression of these diseases. This study will recruit 30 patients with mitochondrial disorders followed in Bordeaux University Hospital and Toulouse University Hospital for who the mutation of mitochondrial DNA has been previously identified. Among classical disease activity information, blood samples will be collected to study immunological parameters. Translational research will be realized on patient' samples to assess immune cell subsets and innate immune cells functions.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria: - General inclusion criteria: - Patient weighing more than 30kg - Person affiliated with or receiving a social security plan; - Patient-specific inclusion criteria: - Patient with molecularly proven primary mitochondrial disease - Free, informed, written consent signed by parental authority holders for minor patients and the investigator prior to any examination required by the research and oral and/or written assent by the participant (depending on age). - Free, informed consent signed by the patient's representative for adult patients under guardianship and the investigator prior to any examination required by the research. - Free, informed consent signed by the patient of legal age and the investigator prior to any examination required by the research - Specific inclusion criteria for controls: - Person who has been informed of the purpose of the study and person matched in age (+/- 5 years) and sex to a patient with primary mitochondrial disease at the time of sampling - Free, informed, and signed consent - Person with no known mitochondrial disease Exclusion Criteria: - Pregnant or breastfeeding women - Refusal to consent to participate in research, - Patients for whom molecular causes have not been formally identified (genetic analyses not performed, or no variant or variant of unknown significance after analysis).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Patient cohort
Collection of 6 blood tubes at the inclusion visit.
Control cohort
Collection of 6 blood tubes at the inclusion visit.

Locations

Country Name City State
France Chu Bordeaux Bordeaux
France Hopital Toulouse Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunological parameters Distribution of several quantitative immunological parameters at inclusion. The following parameters will be considered : Immunoglobulins in g/l (IgG subclasses, IgA, IgM) Inclusion visit
Primary Immunological parameters Distribution of several quantitative immunological parameters at inclusion. The following parameters will be considered : multiplex flow cytometry panels (Th1, Th2, Th17, Tfh, T, B, monocytes) in fluorescence intensity unit Inclusion visit
Secondary Immunological parameters Description of the percentage of patients with abnormal immunological parameters Inclusion visit
Secondary infectious events Incidence of severe or recurrent infectious events retrospectively compared to the general population Inclusion visit
Secondary Biological markers Description of the percentage of patients with abnormal key cytokines (TNF, IL-1b, IL-6, IL-12) Inclusion visit
See also
  Status Clinical Trial Phase
Recruiting NCT06080581 - Mitochondrial Dysfunctions Driving Insulin Resistance
Completed NCT02286856 - DINAMITE Study Nutritional State and Effect Diet in Mitochondrial Disease N/A
Completed NCT01137240 - Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders N/A
Completed NCT00406445 - Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
Enrolling by invitation NCT01803906 - Tissue Sample Study for Mitochondrial Disorders
Recruiting NCT01780168 - The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of Metabolism
Recruiting NCT01694940 - North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Recruiting NCT06080594 - Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance N/A
Completed NCT02804828 - Mitochondrial Cocktail for Gulf War Illness N/A